Patent for Ultra-Sensitive and Rapid Assay System
MENLO PARK, CA, June 22, 2015 — LamdaGen Corporation, a leading developer of diagnostic biosensors, today announced it has received notification from the European Patent Office (EPO) of its intention to grant the patent application entitled “Enzymatic Assays for LSPR” which enables highly sensitive and rapid diagnostic assays.
LamdaGen’s patented nano-based LSPR (Localized Surface Plasmon Resonance) sensors are ideally suited for In-Vitro Diagnostic (IVD) and Point of Care Testing (POCT) systems, facilitating precise quantitation into the low femtomolar range, significantly lower than that of current conventional ELISA assays. This new patent broadly covers nano-plasmonic LSPR surfaces and particles used as solid supports for high-speed and quantitative plasmonic immunoassays.
This EPO allowance, coupled with other patents and patents in process, serves to expand the application and protection of the Company’s core LSPR technologies. “The granting of this patent underscores LamdaGen’s novel ability to harness the significant potential of advanced plasmonics to greatly enhance detection sensitivity, precision and speed over current commercial diagnostics,” commented Randy Storer, CEO and Founder of LamdaGen Corporation. “We are working with a number of global companies to integrate our powerful LSPR sensing technology into existing diagnostic systems, various mobile devices and other advanced IVD systems companies have in development.”
About LamdaGen Corporation
LamdaGen is a private nano-based technology platform company who is the first to produce commercial LSPR products. The products include highly sensitive nano-biosensors for In Vitro Diagnostics, including Central Laboratory based and Point of Care testing for human, veterinary and farm animal health. The Company’s nanotechnology platforms are also purposed for additional scientific applications and products including drug discovery and development and life science research. For more information, visit www.lamdagen.com or email email@example.com